Dogodan Therapeutics, Inc. (DTI)

Genomic medicines for lung diseases and respiratory infections including COVID-19 Cytokine Storm.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Westford, MA 01886, USA
  • Currency USD
  • Founded May 2020
  • Employees 2
  • Incorporation Type C-corp
  • Website Dogodan.com

Company Summary

Genomic medicines are expected to define a new era in medicine producing potentially curative drugs by modifying defective genes. DTI's focus is lung diseases (incl. COVID-19) representing vast global unmet needs. Our platform integrates the latest technologies in genomics, biology and computing to bring new precision medicines to patients. We are raising $1.25M to fund R&D in 2021 to deliver a development candidate for pre-IND studies by 4Q21.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free